

Epigenetics and human disease: translating basic biology into clinical applications

David Rodenhiser, Mellissa Mann

ABSTRACT

Epigenetics refers to the study of heritable changes in gene expression that occur without a change in DNA sequence. Research has shown that epigenetic mechanisms provide an "extra" layer of transcriptional control that regulates how genes are expressed. These mechanisms are critical components in the normal development and growth of cells. Epigenetic abnormalities have been found to be causative factors in cancer, genetic disorders and pediatric syndromes as well as contributing factors in autoimmune diseases and aging. In this review, we examine the basic principles of epigenetic mechanisms and their contribution to human health as well as the clinical consequences of epigenetic errors. In addition, we address the use of epigenetic pathways in new approaches to diagnosis and targeted treatments across the clinical spectrum.

CMAJ 2006;174(3):341-8

The field of genetics has become an integral part of modern medicine in the 50 years since Watson and Crick described their structural model of DNA. In this time, significant advances have been made in identifying specific mutations associated with such human diseases as Huntington's chorea and cystic fibrosis. Further advances, including the Human Genome Project, are providing new opportunities to develop better diagnostic tools and targeted gene therapies.

A new field that will also have an enormous impact on medicine is epigenetics. It is the study of heritable changes in gene function that do not change the DNA sequence but, rather, provide an "extra" layer of transcriptional control that regulates how genes are expressed.¹ This rapidly evolving field offers exciting new opportunities for the diagnosis and treatment of complex clinical disorders. In this review, we will provide clinicians with an understanding of the principles of epigenetic mechanisms and how these principles relate to human health and disease. We will also address the use of epigenetic pathways in new approaches to molecular diagnosis and novel targeted treatments across the clinical spectrum.

Basic principles of epigenetics: DNA methylation and histone modifications

The human genome contains 23 000 genes that must be expressed in specific cells at precise times. Cells manage gene expression by wrapping DNA around clusters (octamers) of globular histone proteins to form nucleosomes (Fig. 1A).² These nucleosomes of DNA and histones are organized into chromatin. Changes to the structure of chromatin influence gene expression: genes are inactivated (switched off) when the chromatin is condensed (silent), and they are expressed (switched on) when chromatin is open (active) (Fig. 1B).³ These dynamic chromatin states are controlled by reversible epigenetic patterns of DNA methylation and histone modifications.⁴ Enzymes involved in this process include DNA methyltransferases (DNMTs), histone deacetylases (HDACs), histone acetylases, histone methyltransferases and the methyl-binding domain protein MECP2. Alterations in these normal epigenetic patterns can deregulate patterns of gene expression, which results in profound and diverse clinical outcomes.

The loss of normal DNA methylation patterns is the best understood epigenetic cause of disease, based on the initial studies during the 1980s that focused on X chromosome inactivation,⁵ genomic imprinting⁶ and cancer.⁴ DNA methylation involves the addition of a methyl group to cytosines within CpG (cytosine/guanine) pairs^{7,8} (Fig. 1A). Typically, unmethylated clusters of CpG pairs are located in tissue-specific genes and in essential "housekeeping" genes, which are involved in routine maintenance roles and are expressed in most tissues. These clusters, or CpG "islands," are targets for proteins that bind to unmethylated CpGs and initiate gene transcription. In contrast, methylated CpGs are generally associated with silent DNA, can block methylation-sensitive proteins and can be easily mutated. DNA methylation patterns are established and maintained by DNMTs, enzymes that are essential for proper gene expression patterns.⁹ In animal experiments, the removal of genes that encode DNMTs is lethal; in humans, overexpression of these enzymes has been linked to a variety of cancers.

In addition to DNA methylation, changes to histone proteins orchestrate DNA organization and gene expression.² Histone-modifying enzymes are recruited to ensure that a recep-

tive DNA region is either accessible for transcription or that DNA is targeted for silencing^{10–12} (Fig. 1B). Active regions of chromatin have unmethylated DNA and have high levels of acetylated histones, whereas inactive regions of chromatin contain methylated DNA and deacetylated histones.² Thus, an epigenetic “tag” is placed on targeted DNA, marking it with a special status that specifically activates or silences genes. These reversible modifications ensure that specific genes can

be expressed or silenced depending on specific developmental or biochemical cues, such as changes in hormone levels, dietary components or drug exposures.^{11,13}

Nature or nurture ... or both?

DNA methylation patterns fluctuate in response to changes in diet, inherited genetic polymorphisms and exposures to envi-




Fig 1: (A) Schematic of epigenetic modifications. Strands of DNA are wrapped around histone octamers, forming nucleosomes. These nucleosomes are organized into chromatin, the building block of a chromosome. Reversible and site-specific histone modifications occur at multiple sites through acetylation, methylation and phosphorylation. DNA methylation occurs at 5-position of cytosine residues in a reaction catalyzed by DNA methyltransferases (DNMTs). Together, these modifications provide a unique epigenetic signature that regulates chromatin organization and gene expression. (B) Schematic of the reversible changes in chromatin organization that influence gene expression: genes are expressed (switched on) when the chromatin is open (active), and they are inactivated (switched off) when the chromatin is condensed (silent).³ White circles = unmethylated cytosines; red circles = methylated cytosines.

ronmental chemicals.^{14,15} Methyl groups are acquired through the diet and are donated to DNA through the folate and methionine pathways.¹⁶ Changes in DNA methylation may occur as a result of low dietary levels of folate, methionine or selenium, which can have profound clinical consequences such as neural tube defects, cancer and atherosclerosis.^{17–21} Such imbalances in dietary nutrients can lead to hypomethylation (which contributes to improper gene expression) and genetic instability (chromosome rearrangements).²¹ For example, hyperhomocysteinemia and global hypomethylation have been observed in vitro in atherosclerosis models, which supports an emerging view that alterations in global methylation patterns are characteristic of early stages of this disease.¹⁹ In advanced stages of atherosclerosis, hyperproliferation may further contribute to DNA hypomethylation and altered gene expression.²²

Environmental agents such as metals (e.g., arsenic) and aromatic hydrocarbons (e.g., benzopyrene) can also destabilize the genome or modify cellular metabolism, or both.^{22,23} These environmental contaminants are found in occupational chemicals, fossil fuel emissions, contaminated drinking water and cigarette smoke.¹⁴ People's sensitivity to diet or to environmental toxins may vary owing to pre-existing genetic variants that can challenge methyl metabolism and predispose a person to epigenetic change. Some reports have linked a common polymorphism in the methylenetetrahydrofolate reductase (*MTHFR*) gene to altered DNA methylation patterns in response to diet, alcohol consumption and hormone replacement and an apparent increased incidence of breast and colorectal cancer in certain populations. For example, the common *MTHFR* 677CT polymorphism has been shown to increase the risk of breast cancer up to 3-fold in premenopausal women.^{24,25} Other studies suggest that the 677TT genotype confers a 40% decreased risk of breast cancer, particularly in postmenopausal women using hormone replacement therapy, by limiting the availability of nucleic acid precursors required by hyperproliferating cells.²⁶ Such examples underscore the complex interplay between epigenetics, the environment (nurture) and genetic individuality (nature) that potentially increase the risk of epigenetic disease.

Clinical consequences of epigenetic errors

Epigenetic mechanisms regulate DNA accessibility throughout a person's lifetime. Immediately following fertilization, the paternal genome undergoes rapid DNA demethylation and histone modifications.²⁷ The maternal genome is demethylated gradually, and eventually a new wave of embryonic methylation is initiated that establishes the blueprint for the tissues of the developing embryo. As a result, each cell has its own epigenetic pattern that must be carefully maintained to regulate proper gene expression. Perturbations in these carefully arranged patterns of DNA methylation and histone modifications can lead to congenital disorders and multisystem pediatric syndromes or predispose people to acquired disease states such as sporadic cancers and neurodegenerative disorders (Box 1).

Box 1: Normal cellular functions regulated in part by epigenetic mechanisms and molecular abnormalities caused by epigenetic errors

Normal functions

- | | |
|--|---|
| • Correct organization of chromatin | Controls active and inactive states of embryonic and somatic cells |
| • Specific DNA methylation and histone modifications | Controls gene- and tissue-specific epigenetic patterns |
| • Silencing repetitive elements | Ensures that chromatin order and proper gene expression patterns are maintained |
| • Genomic imprinting | Is essential for development |
| • X chromosome inactivation | Balances gene expression between males and females |

Abnormalities

- | | |
|-------------------------------------|--|
| • DNA hypermethylation | Results in chromatin condensation and silencing of tumour suppressor and other genes |
| • DNA hypomethylation | Activates oncogenes, results in chromosomal instability, activates transposons |
| • Mutations at methylated cytosines | Results in inappropriate gene expression |
| • Imprinting defects | Results in loss of parental identity |

Genomic imprinting and imprinting disorders

Genomic imprinting allows genes to “remember” whether they were inherited from the mother or the father so that only the maternally or paternally inherited allele is expressed. Imprinting is regulated by DNA methylation and histone modifications⁶ and is important in the context of a variety of developmental and pediatric disorders^{54–58} (Table 1).

Prader–Willi, Angelman and Beckwith–Weidemann syndromes best characterize congenital imprinting disorders.^{54,55} Prader–Willi and Angelman syndromes are caused by genetic and epigenetic errors to the same part of chromosome 15; errors inherited from the father result in Prader–Willi syndrome, and those inherited from the mother, Angelman syndrome.⁵⁴ Beckwith–Wiedemann syndrome is caused by genetic or epigenetic mutations resulting in loss of imprinting on chromosome 11.⁵⁵

Besides gene-specific imprinting effects, global imprinting changes can occur in embryos that completely lack one parental genome (Table 1). For example, spontaneous activation of oocytes in situ leads to ovarian teratomas that lack a paternal genome.⁶⁴ In contrast, complete hydatidiform moles have been found that lack a maternal genome and an embryo and exhibit hyperproliferation of trophoblastic tissues, with the potential of forming choriocarcinoma.⁶⁵ The recessive disorder “familial biparental complete hydatidiform mole” also leads to recurrent development of moles when maternal-specific imprints fail to be established during oogenesis.⁶⁷ Interestingly, imprinting effects that appear to target trophoblast cells have been recently implicated as a cause of pre-eclampsia.⁶⁸

Assisted reproductive technology

Recent evidence suggests that the manipulation of embryos for the purposes of assisted reproduction or cloning may impose inherent risks to normal development. For example, assisted reproductive technologies (ARTs) have been linked to an increased risk of intrauterine growth retardation (odds ratio [OR] 1.59, 95% confidence interval [CI] 1.20–2.11), premature birth (< 33 weeks' gestation, OR 2.99, 95% CI 1.54–5.80; < 37 weeks' gestation, OR 1.93, 95% CI 1.36–2.74), low birth weight (< 1500 g, OR 3.78, 95% CI 4.29–5.75) and prenatal death (OR 2.40, 95% CI 1.59–3.63).^{69,70} Furthermore, an apparent association with ARTs was recently found in registries of children with Angelman syndrome and Beckwith–Wiedemann syndrome.⁷¹ The prevalence of ART use was about 4–9 times greater among children with Beckwith–Wiedemann syndrome than among children in the general

population (OR ≥ 3.2, 95% CI 1.4–7.3). Molecular analyses of patients with Angelman syndrome and Beckwith–Wiedemann syndrome conceived by in vitro fertilization or intracytoplasmic sperm injection revealed a loss of maternal-specific DNA methylation at imprinting centres, which indicates that the errors were epigenetic in nature. Although individually rare, as a group, epigenetic errors may impose significant risk for people conceived by ART. Similarly, in vitro culture in animal models has been found to lead to reduced viability and growth, developmental abnormalities, behavioural changes and loss of imprinting.^{72,73} Such reports suggest that technologies involving the manipulation of cultured embryos may be the “tip of the iceberg” for a wider spectrum of epigenetic alterations.⁷⁴ Further study is required to determine whether epigenetic changes give rise to other imprinting disorders (or to cancer), and why such viability and growth defects appear to occur at increased frequency in the ART population.

Table 1: Associations between epigenetic modifications and human diseases and conditions

Disease/condition	Gene	Biological process	Disease/condition	Gene	Biological process
Cancer			Neurologic		
Bladder	Multiple genes	Hypermethylation ²⁰	Schizophrenia	<i>RELN</i>	Hypermethylation ^{46,47}
Brain (glioma)	<i>RASSF1A</i>	Hypermethylation ^{28,29}	Bipolar disorder	<i>11p?</i>	Unknown ⁴⁸
Brain (glioblast)	<i>MGMT</i>	Hypermethylation ³⁰	Memory formation	Multiple genes	Hypo-, hypermethylation ⁴⁹
Breast	<i>BRCA1</i>	Hypermethylation ³¹	Lupus	Retroviral DNA	Hypomethylation ⁵⁰
Breast	Multiple genes	Hypermethylation ^{32,33}	Cardiovascular		
Cervix	<i>p16</i>	Hypermethylation ³⁴	Atherosclerosis	Multiple genes	Hypo-, hypermethylation ^{19,51}
Colon	Multiple genes	Hypermethylation ²⁰	Homocysteinemia	Multiple genes	Hypomethylation ⁵²
Colorectal	L1 repeats	Hypomethylation ³⁵	Vascular endothelium	<i>eNOS</i>	Hypomethylation ⁵³
Esophagus	<i>CDH1</i>	Hypermethylation ²⁰	Imprinting and pediatric syndromes		
Head/neck	<i>p16, MGMT</i>	Hypermethylation ²⁰	PWS or AS	15q11-q13	Imprinting ⁵⁴
Kidney	<i>TIMP-3</i>	Hypermethylation ²⁰	BWS	11p15	Imprinting ⁵⁵
Leukemia	p15	Hypermethylation ²⁰	SRS	Chromosome 7	Imprinting ⁵⁶
Liver	Multiple genes	Hypermethylation ³⁶	UPD14	14q23-q32	Imprinting ⁵⁷
Lung	<i>p16, p73</i>	Hypermethylation ²⁰	PHP, AHO, MAS	20q13.2	Imprinting ⁵⁸
Lymphoma	<i>DAPK</i>	Hypermethylation ²⁰	Rett syndrome	<i>MECP2</i>	Mutation ⁵⁹
Myeloma	<i>DAPK</i>	Hypermethylation ³⁷	ICF syndrome	<i>DNMT3B</i>	Mutation ⁶⁰
Ovary	<i>BRCA1</i>	Hypermethylation ³⁸	ATRX	<i>ATRX</i>	Chromatin structure ⁶¹
Ovary	<i>Sat2</i>	Hypomethylation ³⁹	FraX	Triplet repeat	Silencing ⁶²
Pancreas	<i>APC</i>	Hypermethylation ²⁰	FSHD	3.3 kb repeat	Chromatin structure ⁶³
Pancreas	Multiple genes	Hypomethylation ⁴⁰	Reproductive		
Prostate	<i>BRCA2</i>	Hypermethylation ^{20,41}	Ovarian teratoma	No paternal genome	Imprinting ⁶⁴
Rhabdomyosarcoma	<i>PAX3</i>	Hypermethylation ⁴²	CHM	No maternal genome	Imprinting ⁶⁵
Stomach	<i>Cyclin D2</i>	Hypomethylation ⁴³	BiCHM	Maternal genome	Imprinting ⁶⁵
Thymus	<i>POMC</i>	Hypomethylation ⁴⁴	Aging		
Urothelial	Satellite DNA	Hypomethylation ⁴⁵		Chromatin	Hypo-, hypermethylation ⁶⁶
Uterus	<i>hMLH1</i>	Hypermethylation ²⁰			

Note: PWS = Prader-Willi syndrome; AS = Angelman syndrome; BWS = Beckwith–Wiedemann syndrome; SRS = Silver-Russell syndrome; UPD14 = uniparental disomy 14; PHP = pseudohypoparathyroidism; AHO = Albright hereditary osteodystrophy; MAS = McCune-Albright syndrome; ICF = immunodeficiency, centromeric instability and facial anomalies; ATRX = α -thalassemia/mental retardation syndrome, X-linked; FraX = Fragile X syndrome; FSHD = facioscapulohumeral muscular dystrophy, CHM = complete hydatidiform mole, BiCHM = familial biparental CHM.

In addition, epigenetic abnormalities, including imprinting defects, are likely responsible for the substantial embryonic losses (up to 98%), placental hyperplasia and respiratory abnormalities observed in animal cloning models.⁷⁵ This may be because, in cloning experiments, the nucleus of a somatic cell must be reprogrammed to the epigenetic state of an embryonic nucleus; genes expressed specifically in somatic cells must be silenced, while those required for embryonic development must be activated. The presence of epigenetic defects in the majority of cloned embryos indicates that the donated nucleus is not efficiently reprogrammed to the epigenetic state of the embryonic nucleus for which it is substituting.^{72,76} In contrast, a recent report showed that imprinting may be preserved in human embryonic stem cells, which suggests that these cells may be better candidates for therapeutic cloning.⁷⁷ A thorough understanding of epigenetic mechanisms and errors is therefore required before ARTs can reach their true potential in assisted reproduction, animal cloning or the engineering of replacement tissue transplants in cases of Parkinson's and other diseases.

Cancer and epigenetic therapies

Cancer is a multistep process in which genetic and epigenetic errors accumulate and transform a normal cell into an invasive or metastatic tumour cell. Altered DNA methylation patterns change the expression of cancer-associated genes (Table 1). DNA hypomethylation activates oncogenes and initiates chromosome instability,^{78–80} whereas DNA hypermethylation initiates silencing of tumour suppressor genes. The incidence of hypermethylation, particularly in sporadic cancers, varies with respect to the gene involved and the tumour type in which the event occurs. For example, *p16^{INK4A}* promoter hypermethylation occurs in varying degrees (9%–49%) in as many as 15 cancer types; in contrast, *BRCA1* hypermethylation is primarily associated with 10%–20% of sporadic breast and ovarian cancers.²⁰ These epigenetic changes can be used in the molecular diagnosis of a variety of cancers.⁸¹

To date, epigenetic therapies are few in number, but several are currently being studied in clinical trials or have been approved for specific cancer types.^{1,82,83} Nucleoside analogues such as azacitidine are incorporated into replicating DNA, inhibit methylation and reactivate previously silenced genes.⁸⁴ Azacitidine has been effective in phase I clinical trials in treating myelodysplastic syndrome and leukemias characterized by gene hypermethylation. For example, 54% of patients with chronic myelogenous leukemia resistant to imatinib exhibited a complete or partial hematologic response, and 46% had a major or minor cytogenetic response to 5-aza-2'-deoxycytidine.⁸⁵ The antisense oligonucleotide MG98 that downregulates DNMT1 is showing promising results in phase I clinical trials⁸⁶ and in targeting solid tumours and renal cell cancer (www.methylgene.com/content.asp?node=14 [accessed 2005 Dec 22]). Molecular analysis of biopsies of head and neck cancer following MG98 treatment revealed demethylation of 2 methylated tumour suppressor genes and methylation of an oncogene. Similarly, small molecules such as valproic acid that downregulate HDACs are being used to

induce growth arrest and tumour cell death. Combination epigenetic therapies (demethylating agents plus HDAC inhibitors) or epigenetic therapy followed by conventional chemotherapy (or immunotherapy) may be more effective since they reactivate silenced genes, including tumour suppressor genes, resensitize drug-resistant cells to standard therapies and act synergistically to kill cancer cells.^{1,82,87} The key challenge for the future will be to limit toxic effects in normal cells and ensure that these novel drug effects reach critical target genes in tumour cells.

Aging

Both increases and decreases in DNA methylation are associated with the aging process, and evidence is accumulating that age-dependent methylation changes are involved in the development of neurologic disorders, autoimmunity and cancer in elderly people.⁸⁸ Methylation changes that occur in an age-related manner may include the inactivation of cancer-related genes. In some tissues, levels of methylated cytosines decrease in aging cells, and this demethylation may promote chromosomal instability and rearrangements, which increases the risk of neoplasia.⁸⁸ In other tissues, such as the intestinal crypts, increased global hypermethylation may be the predisposing event that accounts for the increased risk of colon cancer with advancing age.⁸⁹

Immunity and related disorders

The activation of the immune response involves stepwise epigenetic changes, which allow individual cells to mount a specific immune response that can be maintained over multiple cell generations.^{90,91} For example, shifts in both acetylation and methylation are required to coordinate DNA accessibility and permit recombination, thereby allowing cells to mount an immune response against a specific antigen.⁹² Recent reports suggest that loss of epigenetic control over this complex process contributes to autoimmune disease. Abnormal DNA methylation has been observed in patients with lupus whose T cells exhibit decreased extracellular signal-regulated kinase pathway signalling, decreased methyltransferase activity and hypomethylated DNA.⁹³ Disregulation of this pathway apparently leads to overexpression of methylation-sensitive genes such as the leukocyte function-associated factor (*LFA1*), which causes lupus-like autoimmunity.^{93,94} Interestingly, *LFA1* expression is also required for the development of arthritis, which raises the possibility that altered DNA methylation patterns may contribute to other diseases displaying idiopathic autoimmunity.⁹⁵

Neuropsychiatric disorders

Recent reports have begun to address the role of epigenetic errors in the causation of complex adult psychiatric, autistic and neurodegenerative disorders (Table 1).⁹⁶ Several reports have associated schizophrenia and mood disorders with DNA rearrangements that include the DNMT genes.⁹⁶ *DNMT1* is selectively overexpressed in gamma-aminobutyric acid

(GABA)-ergic interneurons of schizophrenic brains,⁹⁷ whereas hypermethylation has been shown to repress expression of Reelin (a protein required for normal neurotransmission, memory formation and synaptic plasticity) in brain tissue from patients with schizophrenia and patients with bipolar illness and psychosis.⁹⁸ In addition, the HDAC inhibitor valproic acid has been shown to prevent Reelin promoter hypermethylation in a mouse model of schizophrenia.⁹⁹ A role for aberrant methylation mediated by folate levels has been suggested as a factor in Alzheimer's disease; however, there is contradictory evidence regarding hypomethylation and overexpression of the presenilin 1 gene that is involved in synaptic plasticity, long-term memory and neuronal survival.^{100,101} As well, some preliminary evidence supports a model that incorporates both genetic and epigenetic contributions in the causation of autism.¹⁰² Autism has been linked to the region on chromosome 15 that is responsible for Prader-Willi syndrome and Angelman syndrome. Findings at autopsy of brain tissue from patients with autism have revealed deficiency in *MECP2* expression that appears to account for reduced expression of several relevant genes.¹⁰³ These results suggest that *MECP2* deficiency plays a role in chromosome organization in the developing brain in autism, Rett syndrome and several other neurodevelopmental disorders.¹⁰⁴ There may be a role for epigenetics in the diagnosis and treatment of complex neuropsychiatric disorders in the future.

Pediatric syndromes

In addition to epigenetic alterations, specific mutations affecting components of the epigenetic pathway have been identified that are responsible for several syndromes: *DNMT3B* in the ICF (immunodeficiency, centromeric instability and facial anomalies) syndrome,⁶⁰ *MECP2* in Rett syndrome,¹⁰⁵ *ATRX* in ATR-X syndrome (α -thalassemia/mental retardation syndrome, X linked)⁶¹ and DNA repeats in facioscapulohumeral muscular dystrophy⁶³ (Table 1). In Rett syndrome, for example, *MECP2* encodes a protein that binds to methylated DNA; mutations in this protein cause abnormal gene expression patterns within the first year of life. Girls with Rett syndrome display reduced brain growth, loss of developmental milestones and profound mental disabilities.¹⁰⁵ Similarly, the ATR-X syndrome also includes severe developmental deficiencies due to loss of *ATRX*, a protein involved in maintaining the condensed, inactive state of DNA.⁶¹ Together, this constellation of clinical pediatric syndromes is associated with alterations in genes and chromosomal regions necessary for proper neurologic and physical development.

The road ahead

Our increased knowledge of epigenetic mechanisms over the last 10 years is beginning to be translated into new approaches to molecular diagnosis and targeted treatments across the clinical spectrum. With the Human Genome Project completed, the Human Epigenome Project has been proposed and will generate genome-wide methylation maps.¹⁰⁶

By examining both healthy and diseased tissues, specific genomic regions will be identified that are involved in development, tissue-specific expression, environmental susceptibility and pathogenesis. Use of these epigenetic maps will lead to epigenetic therapies for complex disorders across the clinical spectrum.

Our understanding of the role of epigenetic abnormalities in disease processes is still in its infancy. The primary goals over the next decade will include improving our understanding of the interplay between epigenetic mechanisms, gene expression and the environment, and moving from animal models to clinical trials of novel epigenetic therapies directed at a wide variety of diseases. By decreasing the risk of epigenetic instability that leads to disease and by correcting epigenetic abnormalities that predispose to diseases later in life, the promise for epigenetic therapies as an essential treatment option will be fulfilled.

From the EpiGenWestern Research Group at the Children's Health Research Institute (Rodenhiser, Mann) and the Departments of Biochemistry (Rodenhiser, Mann), Paediatrics (Rodenhiser), Oncology (Rodenhiser), and Obstetrics and Gynecology (Mann), University of Western Ontario, and the London Regional Cancer Program, London Health Sciences Centre (Rodenhiser), London, Ont.

Competing interests: None declared.

Contributors: Both authors shared in the writing of this article and revised the manuscript critically for important intellectual content, contributed to the concept and design of the manuscript and gave final approval of the version submitted for publication.

Acknowledgements: We thank our colleagues at the Children's Health Research Institute, the Translational Breast Cancer Research Unit, the London Regional Cancer Program and the EpiGenWestern Research Group, whose support and discussions led to our writing this review. We also thank Drs. Victor Han and Victoria Siu for critical review of this manuscript before submission.

Research by David Rodenhiser cited in this manuscript was funded by the Canadian Breast Cancer Research Alliance.

REFERENCES

1. Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. *Nature* 2004;429:457-63.
2. Peterson CL, Laniel MA. Histones and histone modifications. *Curr Biol* 2004;14: R546-51.
3. Rountree MR, Bachman KE, Herman JG, et al. DNA methylation, chromatin inheritance, and cancer. *Oncogene* 2001;20:3156-65.
4. Feinberg AP, Tycko B. The history of cancer epigenetics. *Nat Rev Cancer* 2004;4: 143-53.
5. Avner P, Heard E. X-chromosome inactivation: counting, choice and initiation. *Nat Rev Genet* 2001;2:59-67.
6. Verona RJ, Mann MR, Bartolomei MS. Genomic imprinting: intricacies of epigenetic regulation in clusters. *Annu Rev Cell Dev Biol* 2003;19:237-59.
7. Ehrlich M, Wang RY. 5-Methylcytosine in eukaryotic DNA. *Science* 1981;212:1350-7.
8. Laird PW, Jaenisch R. DNA methylation and cancer. *Hum Mol Genet* 1994;3: 1487-95.
9. Robertson KD. DNA methylation and chromatin — unravelling the tangled web. *Oncogene* 2002;21:5361-79.
10. Espino PS, Drohic B, Dunn KL, et al. Histone modifications as a platform for cancer therapy. *J Cell Biochem* 2005;94:1088-102.
11. Elgin SC, Grewal SI. Heterochromatin: Silence is golden. *Curr Biol* 2003;13: R895-8.
12. Hendrich B, Guy J, Ramsahoye B, et al. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. *Genes Dev* 2001;15:710-23.
13. Ehrenhofer-Murray AE. Chromatin dynamics at DNA replication, transcription and repair. *Eur J Biochem* 2004;271:2335-49.
14. Luch A. Nature and nurture — lessons from chemical carcinogenesis. *Nat Rev Cancer* 2005;5:113-25.
15. Sutherland JE, Costa M. Epigenetics and the environment. *Ann N Y Acad Sci* 2003; 983:151-60.

16. Ulrey CL, Liu L, Andrews LG, et al. The impact of metabolism on DNA methylation. *Hum Mol Genet* 2005;14(Suppl 1):R139-47.
17. Curtin K, Bigler J, Slattery ML, et al. MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. *Cancer Epidemiol Biomarkers Prev* 2004;13:285-92.
18. Waterland RA, Jirtle RL. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. *Nutrition* 2004;20:63-8.
19. Zaina S, Lindholm MW, Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: More than just hyperhomocysteinemia? *J Nutr* 2005;135:5-8.
20. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. *Cancer Res* 2001;61:3225-9.
21. Friso S, Choi SW. Gene-nutrient interactions and DNA methylation. *J Nutr* 2002;132:2382S-7S.
22. Hiltunen MO, Turunen MP, Hakkinen TP, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. *Vasc Med* 2002;7:5-11.
23. Rossman TG. Mechanism of arsenic carcinogenesis: an integrated approach. *Mutat Res* 2003;533:37-65.
24. Ergul E, Sazci A, Utkan Z, et al. Polymorphisms in the MTHFR gene are associated with breast cancer. *Tumour Biol* 2003;24:286-90.
25. Semenza JC, Delfino RJ, Ziogas A, et al. Breast cancer risk and methylenetetrahydrofolate reductase polymorphism. *Breast Cancer Res Treat* 2003;77:217-23.
26. Le Marchand L, Haiman CA, Wilkens LR, et al. MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study. *Cancer Epidemiol Biomarkers Prev* 2004;13:2071-7.
27. Morgan HD, Santos F, Green K, et al. Epigenetic reprogramming in mammals. *Hum Mol Genet* 2005;14(Suppl 1):R47-58.
28. Uhlmann K, Rohde K, Zeller C, et al. Distinct methylation profiles of glioma subtypes. *Int J Cancer* 2003;106:52-9.
29. Gao Y, Guan M, Su B, et al. Hypermethylation of the RASSF1A gene in gliomas. *Clin Chim Acta* 2004;349:173-9.
30. Bello MJ, Alonso ME, Aminos C, et al. Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. *Mutat Res* 2004;554:23-32.
31. Mancini DN, Rodenhiser DJ, Ainsworth PJ, et al. CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. *Oncogene* 1998;16:1161-9.
32. Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. *Biochem Pharmacol* 2004;68:1187-97.
33. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. *Oncogene* 2002;21:5462-82.
34. Lea JS, Coleman R, Kurien A, et al. Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. *Am J Obstet Gynecol* 2004;190:674-9.
35. Suter CM, Martin DI, Ward RL. Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. *Int J Colorectal Dis* 2004;19:95-101.
36. De Zhu J. The altered DNA methylation pattern and its implications in liver cancer. *Cell Res* 2005;15:272-80.
37. Chim CS, Kwong YL, Fung TK, et al. Methylation profiling in multiple myeloma. *Leuk Res* 2004;28:379-85.
38. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. *J Natl Cancer Inst* 2000;92:564-9.
39. Widschwendter M, Jiang G, Woods C, et al. DNA hypomethylation and ovarian cancer biology. *Cancer Res* 2004;64:4472-80.
40. Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. *Cancer Res* 2003;63:4158-66.
41. Li LC, Okino ST, Dahiya R. DNA methylation in prostate cancer. *Biochim Biophys Acta* 2004;1704:87-102.
42. Kurmasheva RT, Peterson CA, Parham DM, et al. Upstream CpG island methylation of the PAX3 gene in human rhabdomyosarcomas. *Pediatr Blood Cancer* 2005;44:328-37.
43. Oshimo Y, Nakayama H, Ito R, et al. Promoter methylation of cyclin D2 gene in gastric carcinoma. *Int J Oncol* 2003;23:1663-70.
44. Ye L, Li X, Kong X, et al. Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids. *J Endocrinol* 2005;185:337-43.
45. Nakagawa T, Kanai Y, Ushijima S, et al. DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in urothelial carcinomas. *J Urol* 2005;173:243-6.
46. Sharma RP. Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics. *Schizophr Res* 2005;72:79-90.
47. Costa E, Chen Y, Davis J, et al. REELIN and schizophrenia: a disease at the interface of the genome and the epigenome. *Mol Interv* 2002;2:47-57.
48. Petronis A. Epigenetics and bipolar disorder: new opportunities and challenges. *Am J Med Genet C Semin Med Genet* 2003;123:65-75.
49. Levenson JM, Sweatt JD. Epigenetic mechanisms in memory formation. *Nat Rev Neurosci* 2005;6:108-18.
50. Sekigawa I, Okada M, Ogasawara H, et al. DNA methylation in systemic lupus erythematosus. *Lupus* 2003;12:79-85.
51. Lund G, Anderson L, Lauria M, et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. *J Biol Chem* 2004;279:29147-54.
52. Lievers KJ, Kluijtmans LA, Blom HJ. Genetics of hyperhomocysteinemia in cardiovascular disease. *Ann Clin Biochem* 2003;40:46-59.
53. Chan Y, Fish JE, D'Abreo C, et al. The cell-specific expression of endothelial nitric oxide synthase: a role for DNA methylation. *J Biol Chem* 2004;279:35087-100.
54. Nicholls RD, Knepper JL. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. *Annu Rev Genomics Hum Genet* 2001;2:153-75.
55. Weksberg R, Smith AC, Squire J, et al. Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. *Hum Mol Genet* 2003;12(Suppl 1):R61-8.
56. Hitchens MP, Stanier P, Preece MA, et al. Silver-Russell syndrome: a dissection of the genetic aetiology and candidate chromosomal regions. *J Med Genet* 2001;38:810-9.
57. Kamnasaran D, Cox DW. Current status of human chromosome 14. *J Med Genet* 2002;39:81-90.
58. Beaudet AL. Complex imprinting. *Nat Genet* 2004;36:793-5.
59. Van den Veyver IB, Zoghbi HY. Mutations in the gene encoding methyl-CpG-binding protein 2 cause Rett syndrome. *Brain Dev* 2001;23(Suppl 1):S147-51.
60. Ehrlich M. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. *Clin Immunol* 2003;109:17-28.
61. Gibbons RJ, McDowell TL, Raman S, et al. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. *Nat Genet* 2000;24:368-71.
62. Tassone F, Hagerman PJ. Expression of the FMR1 gene. *Cytogenet Genome Res* 2003;100:124-8.
63. Tupler R, Gabellini D. Molecular basis of facioscapulohumeral muscular dystrophy. *Cell Mol Life Sci* 2004;61:557-66.
64. Kuno N, Kadamatsu K, Nakamura M, et al. Mature ovarian cystic teratoma with a highly differentiated homunculus: a case report. *Birth Defects Res A Clin Mol Teratol* 2004;70(1):40-6.
65. Devriendt K. Hydatidiform mole and triploidy: the role of genomic imprinting in placental development. *Hum Reprod Update* 2005;11:137-42.
66. Liu L, Wylie RC, Andrews LG, et al. Aging, cancer and nutrition: the DNA methylation connection. *Mech Ageing Dev* 2003;124:989-98.
67. El-Maarri O, Seoud M, Coullin P, et al. Maternal alleles acquiring paternal methylation patterns in biparental complete hydatidiform moles. *Hum Mol Genet* 2003;12:1405-13.
68. Van Dijk M, Mulders J, Poutsma A, et al. Maternal segregation of the Dutch preclampsia locus at 10q22 with a new member of the winged helix gene family. *Nat Genet* 2005;37:514-9.
69. McDonald SD, Murphy K, Beyene J, et al. Perinatal outcomes of singleton pregnancies achieved by in vitro fertilization: a systematic review and meta-analysis. *J Obstet Gynaecol Can* 2005;27:449-59.
70. Niemitz EL, Feinberg AP. Epigenetics and assisted reproductive technology: a call for investigation. *Am J Hum Genet* 2004;74:599-609.
71. Gicquel C, Gaston V, Mandelbaum J, et al. In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCNOT gene. *Am J Hum Genet* 2003;72(5):1338-41.
72. Mann MR, Chung YG, Nolen LD, et al. Disruption of imprinted gene methylation and expression in cloned preimplantation stage mouse embryos. *Biol Reprod* 2003;69:902-14.
73. Young LE, Fernandez K, McEvoy TG, et al. Epigenetic change in IGF2R is associated with fetal overgrowth after sheep embryo culture. *Nat Genet* 2001;27:153-4.
74. Maher ER, Afnan M, Barratt CL. Epigenetic risks related to assisted reproductive technologies: Epigenetics, imprinting, ART and icebergs? *Hum Reprod* 2003;18:2508-11.
75. Alberio R, Campbell KH. Epigenetics and nuclear transfer. *Lancet* 2003;361:1239-40.
76. Nolen LD, Goa S, Han Z, et al. X chromosome reactivation and regulation in cloned embryos. *Dev Biol* 2005;279:525-40.
77. Rugg-Gunn PJ, Ferguson-Smith AC, Pedersen RA. Epigenetic status of human embryonic stem cells. *Nat Genet* 2005;37:585-7.
78. Kazanietz HH Jr. Mobile elements: drivers of genome evolution. *Science* 2004;303:1626-32.
79. Narayan A, Zhang XY, Marrogi A, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. *Int J Cancer* 1998;77:833-8.
80. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. *Science* 2003;300:489-92.
81. Cottrell SE. Molecular diagnostic applications of DNA methylation technology. *Clin Biochem* 2004;37:595-604.
82. Balch C, Montgomery JS, Paik HI, et al. New anti-cancer strategies: epigenetic therapies and biomarkers. *Front Biosci* 2005;10:1897-931.
83. Laird PW. Cancer epigenetics. *Hum Mol Genet* 2005;14(Suppl 1):R65-76.
84. Esteller M. DNA methylation and cancer therapy: new developments and expectations. *Curr Opin Oncol* 2005;17:55-60.
85. Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine. *Nat Rev Drug Discov* 2005;4:275-6.
86. Davis AJ, Gelmon KA, Siu LL, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. *Invest New Drugs* 2003;21:85-97.
87. Mongan NP, Gudas LJ. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. *Mol Cancer Ther* 2005;4:477-86.
88. Richardson B. Impact of aging on DNA methylation. *Ageing Res Rev* 2003;2:245-61.

89. Rashid A, Issa JP. CpG island methylation in gastroenterologic neoplasia: a maturing field. *Gastroenterology* 2004;127:1578-88.
90. Fitzpatrick DR, Wilson CB. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. *Clin Immunol* 2003;109:37-45.
91. Bergman Y, Cedar H. A stepwise epigenetic process controls immunoglobulin allelic exclusion. *Nat Rev Immunol* 2004;4:753-61.
92. Wilson CB, Makar KW, Shnyreva M, et al. DNA methylation and the expanding epigenetics of T cell lineage commitment. *Semin Immunol* 2005;17:105-19.
93. Oelke K, Richardson B. Decreased T cell ERK pathway signaling may contribute to the development of lupus through effects on DNA methylation and gene expression. *Int Rev Immunol* 2004;23:315-31.
94. Richardson B. DNA methylation and autoimmune disease. *Clin Immunol* 2003;109:72-9.
95. Watts GM, Beurskens FJ, Martin-Padura I, et al. Manifestations of inflammatory arthritis are critically dependent on LFA-1. *J Immunol* 2005;174:3668-75.
96. Abdolmaleky HM, Smith CL, Faraone SV, et al. Methyloomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation. *Am J Med Genet B Neuropsychiatr Genet* 2004;127:51-9.
97. Veldic M, Guidotti A, Maloku E, et al. In psychosis, cortical interneurons over-express DNA-methyltransferase 1. *Proc Natl Acad Sci U S A* 2005;102:2152-7.
98. Chen Y, Sharma RP, Costa RH, et al. On the epigenetic regulation of the human reelin promoter. *Nucleic Acids Res* 2002;30:2930-9.
99. Tremolizzo L, Doueiri MS, Dong E, et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. *Biol Psychiatry* 2005;57:500-9.
100. Fusco A, Seminara L, Cavallaro RA, et al. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. *Mol Cell Neurosci* 2005;28:195-204.
101. Mulder C, Schoonenboom NS, Jansen EE, et al. The transmethylation cycle in the brain of Alzheimer patients. *Neurosci Lett* 2005;386:69-71.
102. Jiang YH, Sahoo T, Michaelis RC, et al. A mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A. *Am J Med Genet A* 2004;131:1-10.
103. Samaco RC, Hogart A, LaSalle JM. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. *Hum Mol Genet* 2005;14:483-92.
104. Thatcher KN, Peddada S, Yasui DH, et al. Homologous pairing of 15q11-13 imprinted domains in brain is developmentally regulated but deficient in Rett and autism samples. *Hum Mol Genet* 2005;14:785-97.
105. Kriaucionis S, Bird A. DNA methylation and Rett syndrome. *Hum Mol Genet* 2003;12(Suppl 2):R221-7.
106. Jones PA, Martienssen R. A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop. *Cancer Res* 2005;65(24):11241-6.

Correspondence to: Dr. David Rodenhiser, Associate Professor, Department of Paediatrics, University of Western Ontario, Rm. A4-134, Victoria Research Tower, 790 Commissioners Rd. E, London ON N6A4L6; fax 519 685-8616; drodenhi@uwo.ca

PHYSICIAN MANAGER INSTITUTE

A five level credit program exclusively for physicians designed to develop superior leadership and management skills

Approved for RCPSC, CFPC, CCHSE credits

In-house PMI

A practical, cost effective and focused training opportunity held on-site for medical leaders and managers

For information:

tel 800 663-7336 or 613 731-8610
x2319 (PMI) or x2261 (In-house PMI)
professional_development@cma.ca

2006 PMI SCHEDULE

PMI I/II

Mar. 5-7/Mar. 8-10	Victoria, BC
Apr. 2-4/Apr. 5-7	Toronto, ON
June 11-13/June 14-16	Ottawa, ON
Sept. 24-26/Sept. 27-29	Calgary, AB

PMI III/IV

Apr. 30-May 2/May 3-5	Niagara-on-the-Lake, ON
Nov. 5-7/Nov. 8-10	Vancouver, BC

PMI V

Oct. 20-22	Vancouver, BC
------------	---------------

ASSOCIATION
MÉDICALE
CANADIENNE



CANADIAN
MEDICAL
ASSOCIATION